As previously reported, JPMorgan analyst Anupam Rama downgraded Rapt Therapeutics (RAPT) to Underweight from Neutral after the company announced the discontinuation of the zelnecirnon program in ...

Shares of RAPT Therapeutics (NASDAQ:RAPT) plunged 44% in early trading Monday after the company said it was scrapping ...

Shares of RAPT Therapeutics (RAPT) plunged 46% Monday after the company said it was scrapping development of its drug ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.

RAPT Therapeutics, Inc. (RAPT) said it is terminating zelnecirnon program. Zelnecirnon was being evaluated in two randomized, ...

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Our expanding ZORYVE portfolio now encompasses psoriasis, seborrheic dermatitis, and atopic dermatitis, providing physicians ...

The unique feline dermatological cases veterinary professionals can see at the clinic, plus how to approach them ...

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...